KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) Operating Expenses (2016 - 2025)

Historic Operating Expenses for TherapeuticsMD (TXMD) over the last 16 years, with Q3 2025 value amounting to $1.6 million.

  • TherapeuticsMD's Operating Expenses fell 208.21% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.5 million, marking a year-over-year decrease of 4530.95%. This contributed to the annual value of $6.5 million for FY2024, which is 3362.85% down from last year.
  • Latest data reveals that TherapeuticsMD reported Operating Expenses of $1.6 million as of Q3 2025, which was down 208.21% from $1.6 million recorded in Q2 2025.
  • TherapeuticsMD's Operating Expenses' 5-year high stood at $60.0 million during Q3 2021, with a 5-year trough of -$77.8 million in Q4 2021.
  • Its 5-year average for Operating Expenses is $8.9 million, with a median of $2.9 million in 2023.
  • In the last 5 years, TherapeuticsMD's Operating Expenses crashed by 25076.74% in 2021 and then soared by 12586.57% in 2022.
  • Over the past 5 years, TherapeuticsMD's Operating Expenses (Quarter) stood at -$77.8 million in 2021, then skyrocketed by 125.87% to $20.1 million in 2022, then crashed by 89.5% to $2.1 million in 2023, then plummeted by 101.56% to -$33000.0 in 2024, then surged by 5087.88% to $1.6 million in 2025.
  • Its last three reported values are $1.6 million in Q3 2025, $1.6 million for Q2 2025, and $1.3 million during Q1 2025.